Levetiracetam

被引：0
|
作者：
不详
机构：
来源：
DRUGS OF THE FUTURE | 2002年 / 27卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Levetiracetam (Keppra(R)), developed by UCB, was approved in the U.S. in 1999 as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. It is also approved in several European countries. Lundbeck holds marketing rights to the drug in Canada, where it is under review by the regulatory authorities (1). The drug is also under evaluation for the treatment of neuropathic pain and migraine.
引用
收藏
页码：419 / 420
页数：2
相关论文
共 50 条
  • [1] Levetiracetam
    Haria, M
    Balfour, JA
    CNS DRUGS, 1997, 7 (02) : 159 - 164
  • [2] Levetiracetam
    Nash, EM
    Sangha, KS
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (13) : 1195 - 1199
  • [3] Levetiracetam
    Salas-Puig, J
    Calleja, S
    NEUROLOGIA, 2001, 16 (09): : 427 - 432
  • [4] Levetiracetam
    Carreno, Mar
    DRUGS OF TODAY, 2007, 43 (11) : 769 - 794
  • [5] Levetiracetam
    Malini Haria
    Julia A. Balfour
    CNS Drugs, 1997, 7 : 159 - 164
  • [6] Levetiracetam
    Beaulieu, Michele J.
    NEONATAL NETWORK, 2013, 32 (04): : 285 - 288
  • [7] LEVETIRACETAM AND PSYCHOSIS
    Trebbau-Lopez, Helena
    Rodriguez-Toledo, Saray
    Reyes-Molon, Laura
    del Rio-Vega, Julia
    ACTAS ESPANOLAS DE PSIQUIATRIA, 2012, 40 (01): : 49 - 49
  • [8] Pharmacokinetics of levetiracetam
    Radtke, RA
    EPILEPSIA, 2001, 42 : 24 - 27
  • [9] Levetiracetam in pediatrics
    Vigevano, F
    JOURNAL OF CHILD NEUROLOGY, 2005, 20 (02) : 87 - 93
  • [10] The safety of levetiracetam
    Sirsi, Deepa
    Safdieh, Joseph E.
    EXPERT OPINION ON DRUG SAFETY, 2007, 6 (03) : 241 - 250
12345